The monet trial: Darunavir/ritonavir with or without nucleoside analogues, for patients with hiv rna below 50 copies/ml

AIDS

Volumn 24, Issue 2, 2010, Pages 223-230

  Arribas, Jose R ^a   Horban, Andrzej ^b   Gerstoft, Jan ^c   Fätkenheuer, Gerdt ^d   Nelson, Mark ^e   Clumeck, Nathan ^f   Pulido, Federico ^g   Hill, Andrew ^h   Van Delft, Yvon ⁱ   Stark, Thomas ^j   Moecklinghoff, Christiane ^j  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Faculty of Power and Aeronautical Engineering   (Poland)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF COLOGNE   (Germany)

^e CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^f SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^g HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

ⁱ Janssen Cilag BV Netherlands   (Netherlands)

^j JANSSEN CILAG GMBH   (Germany)

more..

Author keywords

Darunavir ritonavir; Maintenance; Monotherapy

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR PLUS RITONAVIR; EFAVIRENZ; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; TENOFOVIR PLUS LAMIVUDINE; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHASE 3 CLINICAL TRIAL; POLYPHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD;

EID: 74249086332     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283348944     Document Type: Article

References (28)

1. Hammer S, Eron J, Reiss P, SchooleyR, Thompson M, Walmsley S, et al. Antiretroviral treatment of Adult HIV infection. 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300:555-570.
2. European AIDS Clinical Society (EACS). Guidelines for the clinical management of HIV infected adults in Europe. Available at: http://www. europeanaidsclinicalsociety.org/guidelinespdf/ EACS-EuroGuidelines12mai09.pdf (accessed May 2009).
3. Bierman W, van Agtmael M, Nijhuis M, Danner S, Boucher C. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS 2009; 22:1-13.
4. Hill A, Hirschel B, Katlama C. The Monark trial: where now for boosted protease inhibitor monotherapy? AIDS 2008; 22:777-779.
5. Pulido F, Arribas J, Delgado R, Cabrero E, Gonzalez-Garcia J, Perez-Elias M, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 2008; 22:F1-F9.
6. Shen L, Peterson S, Sedaghat A, McMahon M, Callender M, Zhang H, et al. Dose-response curve slope set class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 2008; 14:762-766.
7. Boffito M, Miralles D, Hill A. Pharmacokinetics, efficacy and safety of darunavir/ritonavir 800/100mg once-daily in treat-ment-näive and experienced patients. HIV Clin Trials 2008; 9:418-427.
8. Mills A, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard P, et al. Once-daily darunavir/ritonavir vs. lopinavir-ritonavir in treatment-näive, HIV-1 infected patients: 96 week analysis of ARTEMIS. AIDS 2009; 23:1679-1688.
9. Madruga J, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomized, controlled Phase III trial. Lancet 2007; 370:49-58.
10. Clotet B, Bellos N, Molina J, Cooper D, Goffard J, Lazzarin A, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomized trials. Lancet 2007; 369:1169-1178.
11. DAIDS 2007. Division of AIDS table for grading the severity of adult and paediatric adverse events. http://rcc.tech.res.com/ DAIDS%20RCC%20Forms/TB- ToxicityTables-DAIDS-AE- GradingTable-FinalDec2004.pdf (accessed March 2007).
12. Hirsch M, Gunthard H, Schapiro J, Brun-Venizet F, Clotet B, Hammer S, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA Panel. Clin Inf Dis 2008; 47:266-285.
13. US Department of Health and Human Services, Food and Drug Administration and Center for Drug Evaluation and Research. Guidance for industry: antiretroviral drugs using plasma HIV RNA measurements: clinical considerations for accelerated and traditional approval. http://www.fda.gov/CDER/GUIDANCE/ 3647fnl.pdf (accessed August 15th, 2007).
14. Piaggio G, Elbourne D, Altman D, Pocock S, Evans S. Reporting of noninferiority and equivalence randomized trials. An extension of the CONSORT statement. J Am Med Assoc 2006; 295:1152-1160.
15. Phillips AN, Walker S. Drug switching and virologic based endpoints in trials of antiretroviral drugs for HIV infection. AIDS 2004; 18:365-370.
16. Roche Diagnostics GmbH, Manhheim, Germany. COBAS Amplicor HIV-1 MONITOR Test, version 1.5. June 2007, Package Insert. http://www.fda.gov/Cber/sba/ hiv1roc122002S.htm (accessed September 2008).
17. Lima V, Harrigan R, Montaner J. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr 2009; 51:3-6.
18. Ribaudo H, Lennox J, Currier J, Kuritzkes D, Gulick R, Haubrich M, et al. Virologic failure endpoint definition in clinical trials: is using HIV-1 RNA threshold <200copies/mL better than <50 copies/mL? An analysis of ACTG studies. 16th Conference on Retroviruses and Opportunistic Infections. Montreal Canada February 2009 [abstr 580].
19. Cooper D, Bloch M, Humphries A, Amin J, Baker D, Emery S, et al. Simplification with fixed-dose tenofovir-emtricitabine or abacavir-lamivudine in adults with suppressed HIV replication (the STEAL study): a randomized, open-label, 96 week, non-inferiority trial. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, February 2009 [abstr 576].
20. Sabin C, Worm S, Weber R, Reiss P, El-Sadr W, Thiebaut R, et al. Recent use of abacavir and didanosine, but not thymidine analogues, is associated with risk of myocardial infarction. 15th Conference on Retroviruses and Opportunistic Infections. (CROI). Boston, USA, February 2008 [abstr. 957c].
21. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191-201.
22. Gupta R, Hill A, Sawyer A, Pillay D. Emergence of Drug resistance in HIV Type 1-infected patients after receipt of first-line highly active antiretroviral therapy: a systematic review of clinical trials. Clin Infect Dis 2008; 47:712-722.
23. Yilmaz A, Izadkhashti A, Price R, Mallon P, De Meulder M, Timmerman P, Gisslen M. Darunavir concentrations in cere-brospinal fluid and blood in HIV-1 infected adults. AIDS Res Hum Retrovir 2009; 25:1-5.
24. Delfraissey J, Flandre P, Delaguerre C, Ghosn J, Horban A, Girard M, et al. Lopinavir/ritonavir monotherapy or plus zido-vudine and lamivudine in antiretroviral-näive HIV-infected patients. AIDS 2008; 22:385-393.
25. Cameron D, da Silva B, Arribas J, Myers R, Bellos N, Gilmore N, et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 2008; 1998:234-240.
26. Wilkin T, McKinnon J, DiRienzo A, Mollan K, Fletcher C, Margolis D, et al. Regimen simplification to atazanavir-ritona-vir alone as maintenance antiretroviral therapy: final 48-week clinical and immunological outcomes. J Infect Dis 2009; 199:866-871.
27. Karlstrom O, Josephson F, Sonnerberg A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J Acquir Immune Defic Syndr 2007; 44:417-422.
28. Gutmann C, Opravil M, Yerly S, Fux C, Furrer H, Cavassani M, et al. Low-nadir CD4 count predicts failure of monotherapy maintenance with ritonavir-boosted lopinavir: results after premature termination of a randomized study due to unexpectedly high failure rate in the monotherapy arm. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, February 2009 [abstr 578].